title: Impact of expression of the uPA system in sarcomas.
abstract: The uPA system mainly comprises the urokinase-type plasminogen activator uPA, the cell-surface receptor uPA receptor and the inhibitor PAI-1. Its clinical and prognostic impact especially in breast cancer is well investigated. In this short report, we summarize the published data describing expression of uPA, PAI-1 and uPA receptor and their relevance to clinical and survival data in sarcomas underlining their impact as tumor biomarkers in this tumor type as well.
authors.affiliation: Clinic of Urology, Division of Molecular Urology, Friedrich-Alexander University Erlangen-Nürnberg, Erlangen, Germany. helge.taubert@uk-erlangen.de
authors.forename: Helge
authors.initials: H
authors.lastname: Taubert
authors.forename: Viktor
authors.initials: V
authors.lastname: Magdolen
authors.forename: Matthias
authors.initials: M
authors.lastname: Kotzsch
mesh_terms: D014408:Biomarkers, Tumor / Q000097:blood / Q000235:genetics; D006801:Humans; D017395:Plasminogen Activator Inhibitor 1 / Q000097:blood* / Q000235:genetics; D017396:Plasminogen Activator Inhibitor 2 / Q000097:blood* / Q000235:genetics; D055293:Receptors, Urokinase Plasminogen Activator / Q000097:blood* / Q000235:genetics; D012509:Sarcoma / Q000097:blood* / Q000201:enzymology / Q000235:genetics; D014568:Urokinase-Type Plasminogen Activator / Q000097:blood / Q000235:genetics*
chemical_list: D014408:Biomarkers, Tumor; D017395:Plasminogen Activator Inhibitor 1; D017396:Plasminogen Activator Inhibitor 2; D055293:Receptors, Urokinase Plasminogen Activator; D014568:Urokinase-Type Plasminogen Activator